CUE

NASD Cue Biopharma, Inc.
Oct 9, 2026 · 3:33 PM ET DELAYED Market Open

$28.55 ↑ +6.22 (+27.85%) Trading Up from the previous close of $22.33, $0.19 below the day’s high of $28.74

YTD change
+211.61%
vs 20-day SMA
-1.06%
vs 200-day SMA
+40.26%

Price ranges

Previous day
$21.60 $22.74
open $22.38 close $22.33
-$0.05 (-0.22%)
Today
$22.10 $28.74
open $22.21 now $28.55
+$6.34 (+28.55%)
Past week
$21.60 $25.94
from $25.25 now $28.55
+$3.30 (+13.07%)
Past month
$21.60 $41.50
from $28.00 now $28.55
+$0.55 (+1.96%)
This year
$0.17 $45.50
from $9.16 now $28.55
+$19.39 (+211.61%)

Price & Performance

+22.04 (+7523.76%) / 6M

$-2.7109$11.81$26.33$40.84Apr 9Jul 10Oct 8

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 97.0% away from all-time highs of $950.70
  • CUE is up 212% since the beginning of the year
  • CUE is up 3% over the past 12 months
  • CUE is up 2% over the past 1 month
  • 4% of all CUE investors are betting against CUE

CUE reads very good: price sits above one of the two key moving averages, the 12-month move is +2310.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-24.14
Earnings momentum -976.1% Quarterly EPS growth
Quarterly change -976.1%

Valuation

P/E ratio N/A
Enterprise value $133.0M
Beta 2.84

Balance sheet & scale

IncomeN/A
Revenue$37.7M
Cash$17.4M
Debt$8.8K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $211.6M

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $407.44 -1.37%
MRNA Moderna, Inc. $197.00 +0.26%
RVMD Revolution Medicines, Inc. $188.12 -6.35%
ROIV Roivant Sciences Ltd. $34.21 -1.55%
BNTX BioNTech SE Sponsored ADR $92.06 -3.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.